Delivery Order SPE2DR25D1205-SPE2DR26F0VT2
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of LEQVIO 284 mg/1.5 mL syringes with a ceiling value of $27,906.60. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, with an ultimate completion date of September 30, 2025. This delivery order is issued under...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of LEQVIO 284 mg/1.5 mL syringes, with a ceiling value of $2,325.55. This is a firm fixed-price delivery order without set-aside designation, reflecting a competitively awarded procurement. The contract specifies performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a...
- The Defense Logistics Agency awarded a $13,953.30 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of LEQVIO 284 mg/1.5 mL syringes. The contract, which is non-set-aside and competitively awarded, carries an ultimate completion date of September 25, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of LEQVIO 284 mg/1.5 mL syringes with a ceiling value of $34,883.25. This non-set-aside, firm fixed-price delivery order is scheduled for completion by November 14, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. LEQVIO is a prescription pharmaceutical product used in cardiovascular treatment, reflecting the Defense Logistics Agency...
- The U.S. Department of Defense's Medical Supply Chain awarded a $4,651.10 delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of LEQVIO 284 mg/1.5 ml syringes. This competitively awarded, firm fixed-price contract is scheduled for completion by October 17, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting the company's proven capability to compete in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $23,255.50 to AmerisourceBergen Drug Corp for the supply of LEQVIO 284 mg/1.5 ml syringes. This competitively awarded, firm fixed-price delivery order is scheduled for completion by November 14, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the contractor's demonstrated capability to compete in open federal...
- The Defense Logistics Agency awarded a $46,511 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of LEQVIO 284 mg/1.5 mL syringes, with an ultimate completion date of September 25, 2025. This competitively awarded contract contains no set-aside designation and specifies performance at AmerisourceBergen's location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $2,325.55 to AmerisourceBergen Drug Corp for LEQVIO 284 mg/1.5 ml syringes on June 26, 2025, with an ultimate completion date of July 18, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on June 18, 2025, by the Defense Logistics Agency (DLA) for the supply of LEQVIO 284 mg/1.5 mL syringes with a ceiling value of $16,278.85. This firm fixed-price delivery order, which is scheduled for completion by July 11, 2025, is unset-aside and competitively awarded. The award represents a continuation of the company's substantial role as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $16,278.85 to AmerisourceBergen Drug Corp for LEQVIO 284 mg/1.5 mL syringes on October 27, 2025, with a completion date of November 18, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- SPE2DR25D1205Indefinite Delivery Contract
- SPE2DR25D1205-SPE2DR26F0VT2Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of LEQVIO 284 mg/1.5 mL syringes with a ceiling value of $4,901.54. This non-set-aside, competitively awarded contract represents a firm fixed-price delivery order with an ultimate completion date of November 18, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, serving customers including the Defense Health Agency and U.S. Coast Guard. AmerisourceBergen's portfolio of federal medical supply contracts demonstrates its established capability to meet federal procurement requirements through open competition, with previous deliveries spanning diabetes medications, neurological treatments, pain management pharmaceuticals, vaccines, and specialized medical supplies across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.9k | 10/27/25 |